Icosavax, a biopharmaceutical company focused on developing vaccines against respiratory diseases, has successfully closed its initial public offering (IPO) of 13,953,332 shares of common stock at $15.00 per share, raising gross proceeds of approximately $209.3 million. This offering included the underwriters' full exercise of an option to purchase an additional 1,819,999 shares. Icosavax aims to leverage its innovative virus-like particle (VLP) technology in its vaccine development pipeline, targeting diseases such as RSV and SARS-CoV-2. The company's stock trades on the Nasdaq under the symbol ICVX.
Icosavax, a biopharmaceutical company specializing in vaccine development, announced the pricing of its upsized initial public offering (IPO) of 12,133,333 shares at $15.00 each, aiming to raise approximately $182 million. The shares are set to trade on Nasdaq under the ticker symbol ICVX starting July 29, 2021, with the offering expected to close on August 2, 2021. The underwriters have a 30-day option to purchase an additional 1,819,999 shares. The company focuses on developing vaccines for respiratory diseases using its innovative virus-like particle technology.